SG11201906663VA - Bone-targeting antibodies - Google Patents
Bone-targeting antibodiesInfo
- Publication number
- SG11201906663VA SG11201906663VA SG11201906663VA SG11201906663VA SG11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA SG 11201906663V A SG11201906663V A SG 11201906663VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- antibodies
- bridgewater
- sanofi
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448763P | 2017-01-20 | 2017-01-20 | |
| PCT/US2018/014350 WO2018136698A2 (fr) | 2017-01-20 | 2018-01-19 | Anticorps de ciblage osseux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906663VA true SG11201906663VA (en) | 2019-08-27 |
Family
ID=61581744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906663VA SG11201906663VA (en) | 2017-01-20 | 2018-01-19 | Bone-targeting antibodies |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10844115B2 (fr) |
| EP (1) | EP3571226A2 (fr) |
| JP (2) | JP7227138B2 (fr) |
| KR (2) | KR20230172039A (fr) |
| CN (2) | CN118121696A (fr) |
| AR (1) | AR110755A1 (fr) |
| AU (1) | AU2018210270A1 (fr) |
| BR (1) | BR112019013986A2 (fr) |
| CA (1) | CA3050884A1 (fr) |
| IL (1) | IL268114A (fr) |
| MX (2) | MX2019008549A (fr) |
| MY (1) | MY194819A (fr) |
| SG (1) | SG11201906663VA (fr) |
| TW (3) | TWI788321B (fr) |
| UY (1) | UY37576A (fr) |
| WO (1) | WO2018136698A2 (fr) |
| ZA (1) | ZA201907673B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533003A (ja) * | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TW202019962A (zh) * | 2018-07-10 | 2020-06-01 | 法商賽諾菲公司 | 標靶CD38及TGF-β的組合療法 |
| WO2020104390A2 (fr) * | 2018-11-19 | 2020-05-28 | Biocartis Nv | Détection améliorée d'acides nucléiques à faible nombre de copies dans un flux de travail intégré |
| IL308175A (en) | 2021-05-07 | 2023-12-01 | Baylor College Medicine | Treatment of moderate to severe defective bone formation |
| EP4373522A1 (fr) * | 2021-07-20 | 2024-05-29 | William Marsh Rice University | Compositions modifiées pour une thérapie ciblant les os |
| AU2022379208A1 (en) * | 2021-11-01 | 2024-06-13 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| WO1994013804A1 (fr) | 1992-12-04 | 1994-06-23 | Medical Research Council | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| CN103275221B (zh) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| EP1074563A1 (fr) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Polypeptides chimériques augmentant la formation de dimères par des interactions électrostatiques et des ponts disulfures, méthode pour les produire et leurs utilisations |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| WO2004060920A1 (fr) | 2002-12-31 | 2004-07-22 | Altus Pharmaceuticals Inc. | Complexes de cristaux proteiques et de polymeres ioniques |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| WO2005010049A2 (fr) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Compositions de liaison et reactifs associes |
| JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック， インコーポレイテッド | ヒト化抗ＴＧＦ−β抗体 |
| EP1759001B1 (fr) | 2004-04-21 | 2011-04-13 | Enobia Pharma Inc. | Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines vers l'os |
| LT1850873T (lt) | 2005-02-08 | 2019-04-10 | Genzyme Corporation | Antikūnas prieš tgf beta |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| WO2008145142A1 (fr) | 2007-05-31 | 2008-12-04 | Genmab A/S | Anticorps igg4 stables |
| US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| ES2689274T3 (es) | 2008-01-03 | 2018-11-13 | The Scripps Research Institute | Dirección de anticuerpos mediante un dominio de reconocimiento modular |
| SI2350129T1 (sl) | 2008-08-25 | 2015-11-30 | Amplimmune, Inc. | Sestavki PD-1 antagonistov in postopek njihove uporabe |
| PL2379600T5 (pl) | 2008-12-22 | 2021-03-08 | Novo Nordisk A/S | Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego |
| ES2598006T3 (es) | 2009-04-24 | 2017-01-24 | Vanderbilt University | Anticuerpos anti-TGF-beta para la inducción del crecimiento óseo |
| DK2542590T4 (da) | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| CN103608040B (zh) | 2011-04-20 | 2017-03-01 | 米迪缪尼有限公司 | 结合b7‑h1和pd‑1的抗体和其他分子 |
| KR102148982B1 (ko) | 2011-06-03 | 2020-08-27 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
| BR112013031892A2 (pt) | 2011-06-13 | 2016-11-22 | Abgenomics Cooperatief Ua | anticorpos anti-psgl-1 e seu uso |
| CA2852874A1 (fr) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprenant une phosphatase alcaline et/ou un peptide natriuretique et leurs procedes d'utilisation |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) * | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| DK2855527T3 (en) | 2012-05-31 | 2018-11-26 | Innate Pharma | TLR3 BINDERS |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014062978A1 (fr) | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Signatures moléculaires du cancer de l'ovaire |
| LT2976359T (lt) * | 2013-03-20 | 2018-12-27 | Genzyme Corporation | Nebaigtinės osteogenezės gydymo būdai |
| PT2981822T (pt) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Composições e métodos para modulação do fator de crescimento |
| CN112457403B (zh) | 2013-09-13 | 2022-11-29 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| KR20160089531A (ko) | 2013-12-17 | 2016-07-27 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 항-her2 항체를 사용하여 her2-양성 암을 치료하는 방법 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170216401A1 (en) * | 2014-03-17 | 2017-08-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| WO2016161410A2 (fr) | 2015-04-03 | 2016-10-06 | Xoma Technology Ltd. | Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1 |
| AU2016249395B2 (en) | 2015-04-17 | 2022-04-07 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-PD-1 antibody and another antibody |
| WO2017011773A2 (fr) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Acides nucléiques à codons optimisés codant des anticorps |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| JP2019533003A (ja) | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
-
2018
- 2018-01-18 AR ARP180100119A patent/AR110755A1/es unknown
- 2018-01-18 TW TW107101790A patent/TWI788321B/zh active
- 2018-01-18 TW TW113101673A patent/TW202421659A/zh unknown
- 2018-01-18 TW TW111146907A patent/TWI832600B/zh active
- 2018-01-19 AU AU2018210270A patent/AU2018210270A1/en not_active Abandoned
- 2018-01-19 EP EP18709437.0A patent/EP3571226A2/fr active Pending
- 2018-01-19 WO PCT/US2018/014350 patent/WO2018136698A2/fr unknown
- 2018-01-19 BR BR112019013986-9A patent/BR112019013986A2/pt not_active IP Right Cessation
- 2018-01-19 KR KR1020237042558A patent/KR20230172039A/ko not_active Application Discontinuation
- 2018-01-19 CN CN202410319667.1A patent/CN118121696A/zh active Pending
- 2018-01-19 UY UY0001037576A patent/UY37576A/es not_active Application Discontinuation
- 2018-01-19 US US15/875,125 patent/US10844115B2/en active Active
- 2018-01-19 MY MYPI2019006821A patent/MY194819A/en unknown
- 2018-01-19 SG SG11201906663VA patent/SG11201906663VA/en unknown
- 2018-01-19 KR KR1020197024021A patent/KR102613463B1/ko active IP Right Grant
- 2018-01-19 MX MX2019008549A patent/MX2019008549A/es unknown
- 2018-01-19 JP JP2019539277A patent/JP7227138B2/ja active Active
- 2018-01-19 CN CN201880007783.2A patent/CN111032690B/zh active Active
- 2018-01-19 CA CA3050884A patent/CA3050884A1/fr active Pending
-
2019
- 2019-07-16 IL IL268114A patent/IL268114A/en unknown
- 2019-07-17 MX MX2022008073A patent/MX2022008073A/es unknown
- 2019-11-20 ZA ZA2019/07673A patent/ZA201907673B/en unknown
-
2020
- 2020-10-23 US US17/079,285 patent/US12098194B2/en active Active
-
2023
- 2023-02-08 JP JP2023017271A patent/JP2023058590A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906663VA (en) | Bone-targeting antibodies | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
| SG11202000073XA (en) | Anti-cd8 antibodies and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201804178YA (en) | Pd1 and/or lag3 binders | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201907209QA (en) | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | |
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201901220XA (en) | Methods of processing a fluid including a recombinant therapeutic protein and use thereof | |
| SG11201909957TA (en) | Engineered ligase variants | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201909561RA (en) | Octree-based convolutional neural network | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis |